UroGen Pharma is a biopharmaceutical company that develops and commercialises treatments for cancers and other diseases of the urinary tract. Its main product is a gel formulation of a chemotherapy drug that is delivered directly into the bladder to treat a type of low-grade bladder cancer, and it is also developing similar treatments for other urothelial conditions. The company is based in Israel and the United States and serves urologists and their patients.
The shares are listed on the London Exchange in UK under the code 0XOD, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #2315 of 3787 on the London Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendFair
68/100
Mixed trend against its averages.
See the numbers →
Above 200-day average11.2%
From 52-week high-31.7%
MomentumFair
52/100
Typical recent returns for this exchange.
See the numbers →
3-month return-19.5%
6-month return33.6%
Stability (higher is calmer)Weak
29/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)60.4%
Worst drawdown, 1 year (smaller is calmer)-34.8%
LiquidityWeak
25/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.06M USD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 16.19 – 51.11Daily closes, split-adjusted
Signals
50-day average42.25
200-day average31.02
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.76
Technical summary
Daily
Bearish
4 bullish · 1 neutral · 10 bearish
Weekly
Strongly bearish
1 bullish · 1 neutral · 5 bearish
Monthly
Strongly bullish
1 bullish · 0 neutral · 0 bearish
Moving averages (daily)
SMA 10
36.25
Bearish
EMA 10
36.27
Bearish
SMA 20
38.42
Bearish
EMA 20
37.96
Bearish
SMA 50
42.25
Bearish
EMA 50
39.90
Bearish
SMA 100
39.95
Bearish
EMA 100
38.35
Bearish
SMA 200
31.02
Bullish
EMA 200
–
n/a
Oscillators (daily)
RSI (14)
32.33
Neutral
MACD (12, 26)
-2.03
Bearish
Momentum (12)
-17.43
Bearish
Stochastic %K (14)
9.32
Bullish
Williams %R (14)
-90.68
Bullish
CCI (20)
-106.5
Bullish
Pivot points (classic, last session)
S3
33.21
S2
33.83
S1
34.16
Pivot
34.78
R1
35.10
R2
35.72
R3
36.05
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in USD. Educational only, not financial advice.
